{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:46:28Z","timestamp":1792691188721,"version":"4.5.0"},"reference-count":119,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) caused an outbreak in 2002-2003, spreading to 29 countries with a mortality rate of about 10%. Strict quarantine and infection control methods quickly stopped the spread of the disease. Later research showed that SARS-CoV came from animals (zoonosis) and stressed the possibility of a similar spread from host to human, which was clearly shown by the COVID-19 outbreak. The COVID-19 pandemic, instigated by SARS-CoV-2, has affected 776 million confirmed cases and more than seven million deaths globally as of Sept 15, 2024. The existence of animal reservoirs of coronaviruses continues to pose a risk of re-emergence with improved fitness and virulence. Given the high death rate (up to 70 percent) and the high rate of severe sickness (up to 68.7 percent in long-COVID patients), it is even more critical to identify new therapies as soon as possible. This study combines research on antivirals that target SARS coronaviruses that have been conducted over the course of more than twenty years. It is a beneficial resource that might be useful in directing future studies.<\/jats:p>","DOI":"10.3389\/fcimb.2025.1520811","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T06:58:20Z","timestamp":1737615500000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Advancements in the development of antivirals against SARS-Coronavirus"],"prefix":"10.3389","volume":"15","author":[{"given":"Mrityunjay","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirza Sarwar","family":"Baig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanchan","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12985-023-02210-z","article-title":"What are the current anti-COVID-19 drugs? From traditional to smart molecular mechanisms","volume":"20","author":"Aboul-Fotouh","year":"2023","journal-title":"Virol. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"8017","DOI":"10.1128\/JVI.00998-13","article-title":"Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms","volume":"87","author":"Adedeji","year":"2013","journal-title":"J. Virol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e74877","DOI":"10.7554\/eLife.74877","article-title":"Drug targeting Nsp1-ribosomal complex shows antiviral activity against SARS-CoV-2","volume":"11","author":"Afsar","year":"2022","journal-title":"eLife."},{"key":"B4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.antiviral.2006.10.008","article-title":"Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a\/7b, 3a\/3b and S","volume":"73","author":"\u00c5kerstr\u00f6m","year":"2007","journal-title":"Antiviral Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"4879","DOI":"10.1080\/07391102.2020.1863265","article-title":"Prediction of potential inhibitors against SARS-CoV-2 endoribonuclease: RNA immunity sensing","volume":"40","author":"Al-Rashedi","year":"2022","journal-title":"J. Biomolecular Structure Dynamics."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.143129","article-title":"Dissecting strategies to tune the therapeutic potential of SARS-CoV-2\u2013specific monoclonal antibody CR3022","volume":"6","author":"Atyeo","year":"2021","journal-title":"JCI Insight"},{"key":"B7","doi-asserted-by":"publisher","first-page":"12305","DOI":"10.1080\/07391102.2023.2175255","article-title":"In silico analysis reveals hypoxia-induced miR-210-3p specifically targets SARS-CoV-2 RNA","volume":"41","author":"Baig","year":"2023","journal-title":"J. Biomolecular Structure Dynamics."},{"key":"B8","first-page":"337","article-title":"Differential binding of SARS-CoV-2 Spike protein variants to its cognate receptor hACE2 using molecular modeling based binding analysis","volume":"17","author":"Baig","year":"2021","journal-title":"Bioinformation."},{"key":"B9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.antiviral.2006.03.005","article-title":"Inhibition of feline (FIPV) and human (SARS) coronavirus by semisynthetic derivatives of glycopeptide antibiotics","volume":"72","author":"Balzarini","year":"2006","journal-title":"Antiviral Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1080\/07391102.2020.1841026","article-title":"Identification and characterisation of novel RdRp and Nsp15 inhibitors for SARS-COV2 using computational approach","volume":"40","author":"Barage","year":"2022","journal-title":"J. Biomolecular Structure Dynamics."},{"key":"B11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.antiviral.2006.03.001","article-title":"Enhancement of the infectivity of SARS-CoV in BALB\/c mice by IMP dehydrogenase inhibitors, including ribavirin","volume":"71","author":"Barnard","year":"2006","journal-title":"Antiviral Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/095632020401500102","article-title":"Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and \u03b2-D-N 4 -hydroxycytidine","volume":"15","author":"Barnard","year":"2004","journal-title":"Antivir Chem. Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1128\/AAC.48.5.1766-1772.2004","article-title":"In vitro activity of expanded-spectrum pyridazinyl oxime ethers related to pirodavir: novel capsid-binding inhibitors with potent antipicornavirus activity","volume":"48","author":"Barnard","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"173779","DOI":"10.1016\/j.ejphar.2020.173779","article-title":"Drug designing against\u00a0NSP15 of SARS-COV2 via high throughput computational screening and structural dynamics approach","volume":"892","author":"Batool","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: An update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antiviral Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/bcpt.v128.2","article-title":"Camostat mesylate against SARS-CoV-2 and COVID-19\u2014Rationale, dosing and safety","volume":"128","author":"Breining","year":"2021","journal-title":"Basic Clin. Pharma Tox."},{"key":"B17","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.cell.2020.05.025","article-title":"Potent neutralising\u00a0antibodies against SARS-coV-2 identified by high-throughput single-cell sequencing of convalescent patients\u2019 B cells","volume":"182","author":"Cao","year":"2020","journal-title":"Cell."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e23582","DOI":"10.1097\/MD.0000000000023582","article-title":"Anti-IL6 treatment of serious COVID-19 disease: A monocentric retrospective experience","volume":"100","author":"Castelnovo","year":"2021","journal-title":"Medicine."},{"key":"B20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterisation of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"B21","doi-asserted-by":"publisher","first-page":"ofaa241","DOI":"10.1093\/ofid\/ofaa241","article-title":"Antiviral activity and safety of darunavir\/cobicistat for the treatment of COVID-19","volume":"7","author":"Chen","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(03)13973-6","article-title":"Treatment of SARS with human interferons","volume":"362","author":"Cinatl","year":"2003","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/asia.201900841","article-title":"New nucleoside analogues for the treatment of hemorrhagic fever virus infections","volume":"14","author":"De Clercq","year":"2019","journal-title":"Chem. Asian J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"155934","DOI":"10.1016\/j.cyto.2022.155934","article-title":"Inflammasomes and IL-1 family cytokines in SARS-CoV-2 infection: from prognostic marker to therapeutic agent","volume":"157","author":"Declercq","year":"2022","journal-title":"Cytokine."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.3390\/jcm9072084","article-title":"SARS-coV-2: repurposed drugs and novel therapeutic approaches\u2014Insights into chemical structure\u2014Biological activity and toxicological screening","volume":"9","author":"Dehelean","year":"2020","journal-title":"J. Clin. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5657","DOI":"10.1080\/07391102.2020.1792992","article-title":"Identification of potential drugs against SARS-CoV-2 nonstructural protein 1 (nsp1)","volume":"39","author":"De Lima Menezes","year":"2021","journal-title":"J. Biomolecular Structure Dynamics."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1099\/vir.0.052910-0","article-title":"MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-\u03b1 treatment","volume":"94","author":"De Wilde","year":"2013","journal-title":"J. Gen. Virology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1099\/vir.0.034983-0","article-title":"Cyclosporin A inhibits the replication of diverse coronaviruses","volume":"92","author":"De Wilde","year":"2011","journal-title":"J. Gen. Virology."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1007\/s11030-022-10576-5","article-title":"Evaluation of action of steroid molecules on SARS-CoV-2 by inhibiting NSP-15, an endoribonuclease","volume":"27","author":"Dhanabalan","year":"2023","journal-title":"Mol. Divers."},{"key":"B31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s12551-016-0205-y","article-title":"DNA supercoiling is a fundamental regulatory principle in the control of bacterial gene expression","volume":"8","author":"Dorman","year":"2016","journal-title":"Biophys. Rev."},{"key":"B32","doi-asserted-by":"publisher","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"m1432","DOI":"10.1136\/bmj.m1432","article-title":"Chloroquine and hydroxychloroquine in covid-19","author":"Ferner","year":"2020","journal-title":"BMJ"},{"key":"B34","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Japan Acad. Ser. B: Phys. Biol. Sci."},{"key":"B35","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.peptides.2005.09.006","article-title":"Synthesis and activity of an octapeptide inhibitor designed for SARS coronavirus main proteinase","volume":"27","author":"Gan","year":"2006","journal-title":"Peptides."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1111\/febs.v287.17","article-title":"Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing","volume":"287","author":"Glebov","year":"2020","journal-title":"FEBS J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"11779322211025876","DOI":"10.1177\/11779322211025876","article-title":"Structure and function of major SARS-coV-2 and SARS-coV proteins","volume":"15","author":"Gorkhali","year":"2021","journal-title":"Bioinform. Biol. Insights"},{"key":"B38","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1056\/NEJMoa2116846","article-title":"Early remdesivir to prevent progression to severe covid-19 in outpatients","volume":"386","author":"Gottlieb","year":"2022","journal-title":"N Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1930636","DOI":"10.1080\/19420862.2021.1930636","article-title":"A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351","volume":"13","author":"Gu","year":"2021","journal-title":"mAbs."},{"key":"B40","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.antiviral.2009.12.001","article-title":"TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds","volume":"85","author":"Haga","year":"2010","journal-title":"Antiviral Res."},{"key":"B41","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2901-9","article-title":"Identification of SARS-CoV-2 inhibitors using lung and colonic organoids","volume":"589","author":"Han","year":"2021","journal-title":"Nature."},{"key":"B42","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1099\/vir.0.061911-0","article-title":"Interferon-\u03b2 and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays","volume":"95","author":"Hart","year":"2014","journal-title":"J. Gen. Virology."},{"key":"B43","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.plgene.2017.05.013","article-title":"miRNA mediated regulation of NAC transcription factors in plant development and environment stress response","volume":"11","author":"Hern\u00e1ndez","year":"2017","journal-title":"Plant Gene."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1021\/jm0493008","article-title":"Antiviral activity of glycyrrhizic acid derivatives against SARS\u2013coronavirus","volume":"48","author":"Hoever","year":"2005","journal-title":"J. Med. Chem."},{"key":"B45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-coV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell."},{"key":"B46","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1161\/01.HYP.0000146120.29648.36","article-title":"Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor","volume":"44","author":"Huentelman","year":"2004","journal-title":"Hypertension."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e0289890","DOI":"10.1371\/journal.pone.0289890","article-title":"Polypharmacology guided drug repositioning approach for SARS-CoV2","volume":"18","author":"Jamir","year":"2023","journal-title":"PloS One"},{"key":"B49","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature."},{"key":"B50","doi-asserted-by":"publisher","first-page":"610","DOI":"10.2174\/1570180817999201211191445","article-title":"Selection of active antiviral compounds against COVID-19 disease targeting coronavirus endoribonuclease nendou\/NSP15 via ligandbased virtual screening and molecular docking","volume":"18","author":"Joshi","year":"2021","journal-title":"LDDD."},{"key":"B51","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1080\/07391102.2020.1814870","article-title":"Identification of promising antiviral drug candidates against nonstructural protein 15 (NSP15) from SARS-CoV-2: anin silicoassisted drug-repurposing study","volume":"40","author":"Khan","year":"2022","journal-title":"J. Biomolecular Structure Dynamics."},{"key":"B52","doi-asserted-by":"publisher","first-page":"11754","DOI":"10.1128\/JVI.01348-12","article-title":"Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses","volume":"86","author":"Kim","year":"2012","journal-title":"J. Virol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ymeth.2021.02.017","article-title":"Multi-targeting approach for nsp3, nsp9, nsp12 and nsp15 proteins of SARS-CoV-2 by Diosmin as illustrated by molecular docking and molecular dynamics simulation methodologies","volume":"195","author":"Kumar","year":"2021","journal-title":"Methods."},{"key":"B54","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.virol.2007.11.028","article-title":"Curcumin inhibits herpes simplex virus immediate-early gene expression by a mechanism independent of p300\/CBP histone acetyltransferase activity","volume":"373","author":"Kutluay","year":"2008","journal-title":"Virology."},{"key":"B55","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.antiviral.2019.03.010","article-title":"Significant inhibition of re-emerged and emerging swine enteric coronavirus in vitro using the multiple shRNA expression vector","volume":"166","author":"Li","year":"2019","journal-title":"Antiviral Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.peptides.2011.05.015","article-title":"Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses","volume":"32","author":"Li","year":"2011","journal-title":"Peptides."},{"key":"B57","doi-asserted-by":"publisher","first-page":"104704","DOI":"10.1016\/j.antiviral.2020.104704","article-title":"Deguelin inhibits HCV replication through suppressing cellular autophagy via down regulation of Beclin1 expression in human hepatoma cells","volume":"174","author":"Liao","year":"2020","journal-title":"Antiviral Res."},{"key":"B58","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.antiviral.2017.12.015","article-title":"Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes","volume":"150","author":"Lin","year":"2018","journal-title":"Antiviral Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1021\/acsptsci.0c00130","article-title":"Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-coV-2 main protease inhibitors","volume":"3","author":"Ma","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2217\/fvl-2020-0233","article-title":"Targeting SARS-coV-2 nonstructural protein 15 endoribonuclease: an in silico perspective","volume":"16","author":"Mahmud","year":"2021","journal-title":"Future Virology."},{"key":"B61","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s42003-020-01577-x","article-title":"Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential\u00a0anti-SARS-CoV-2 agents","volume":"4","author":"Mody","year":"2021","journal-title":"Commun. Biol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomised, controlled trial of ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl. J. Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"106499","DOI":"10.1016\/j.ijantimicag.2021.106499","article-title":"Effects of simeprevir on the replication of SARS-CoV-2 in vitro and in transgenic hACE2 mice","volume":"59","author":"Muturi","year":"2022","journal-title":"Int. J. Antimicrobial Agents."},{"key":"B64","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3390\/v14050961","article-title":"Antiviral drug discovery for the treatment of COVID-19 infections","volume":"14","author":"Ng","year":"2022","journal-title":"Viruses."},{"key":"B65","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/v10110614","article-title":"The natural flavonoid compound deguelin inhibits HCMV lytic replication within fibroblasts","volume":"10","author":"Nukui","year":"2018","journal-title":"Viruses."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1128\/JVI.02322-09","article-title":"Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family coronaviridae","volume":"84","author":"O\u2019Keefe","year":"2010","journal-title":"J. Virol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"106177","DOI":"10.1016\/j.ijantimicag.2020.106177","article-title":"Design of novel viral attachment inhibitors of the spike glycoprotein (S) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through virtual screening and dynamics","volume":"56","author":"Oany","year":"2020","journal-title":"Int. J. Antimicrobial Agents."},{"key":"B68","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijbiomac.2020.09.204","article-title":"Novel insights into the treatment of SARS-CoV-2 infection: an overview of current clinical trials","volume":"165","author":"Oroojalian","year":"2020","journal-title":"Int. J. Biol. Macromolecules."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2:125","DOI":"10.2147\/VAAT.S12733","article-title":"Small molecule inhibitors of the SARS-CoV Nsp15 endoribonuclease","author":"Ortiz-Alcantara","year":"2010","journal-title":"Virus Adaptation Treat."},{"key":"B70","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1016\/j.bmcl.2015.05.039","article-title":"Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity","volume":"25","author":"Peters","year":"2015","journal-title":"Bioorganic Medicinal Chem. Letters."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002331","article-title":"The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors","volume":"7","author":"Pfefferle","year":"2011","journal-title":"Denison MR editor. PloS Pathog."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.3390\/molecules25071577","article-title":"Antioxidant potential of antiviral drug umifenovir","volume":"25","author":"Proskurnina","year":"2020","journal-title":"Molecules."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1128\/AAC.01598-05","article-title":"Inhibition of human coronavirus NL63 infection at early stages of the replication cycle","volume":"50","author":"Pyrc","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"B74","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.chest.2020.10.009","article-title":"Use of ivermectin is associated with lower mortality in hospitalised patients with coronavirus disease 2019","volume":"159","author":"Rajter","year":"2021","journal-title":"Chest."},{"key":"B75","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1016\/j.bmcl.2010.04.118","article-title":"Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease","volume":"20","author":"Ramajayam","year":"2010","journal-title":"Bioorganic Medicinal Chem. Letters."},{"key":"B76","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","article-title":"Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing","volume":"586","author":"Riva","year":"2020","journal-title":"Nature."},{"key":"B77","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jiph.2016.04.001","article-title":"Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus","volume":"9","author":"Rossignol","year":"2016","journal-title":"J. Infection Public Health"},{"key":"B78","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.antiviral.2005.01.003","article-title":"Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus","volume":"66","author":"Saijo","year":"2005","journal-title":"Antiviral Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.drudis.2020.09.013","article-title":"Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms","volume":"25","author":"Sanghai","year":"2020","journal-title":"Drug Discovery Today"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.01818","article-title":"Antivirals against coronaviruses: candidate drugs for SARS-coV-2 treatment","volume":"11","author":"Santos","year":"2020","journal-title":"Front. Microbiol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3390\/microorganisms10020342","article-title":"The nsp15 nuclease as a good target to combat SARS-coV-2: mechanism of action and its inactivation with FDA-approved drugs","volume":"10","author":"Saramago","year":"2022","journal-title":"Microorganisms."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/jalm\/jfac064","article-title":"Characterisation of casirivimab plus imdevimab, sotrovimab, and bamlanivimab plus etesevimab-derived interference in serum protein electrophoresis and immunofixation electrophoresis","volume":"7","author":"Scholl","year":"2022","journal-title":"J. Appl. Lab. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1124\/mol.110.064261","article-title":"A Small-Molecule Oxocarbazate Inhibitor of Human Cathepsin L Blocks Severe Acute Respiratory Syndrome and Ebola Pseudotype Virus Infection into Human Embryonic Kidney 293T cells","volume":"78","author":"Shah","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"33:2179","DOI":"10.36721\/PJPS.2020.33.5.REG.2179-2186.1","article-title":"Vitamin D is a potential inhibitor of COVID-19: In silico molecular docking to the binding site of SARS-CoV-2 endoribonuclease Nsp15","author":"Shalayel","year":"2020","journal-title":"Pakistan J. Pharm. Sci."},{"key":"B85","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1080\/07391102.2020.1808077","article-title":"In-silico screening of plant-derived antivirals against main protease, 3CLpro and endoribonuclease, NSP15 proteins of SARS-CoV-2","volume":"40","author":"Sharma","year":"2022","journal-title":"J. Biomolecular Structure Dynamics."},{"key":"B86","doi-asserted-by":"publisher","first-page":"128933","DOI":"10.1016\/j.foodchem.2020.128933","article-title":"An in-silico evaluation of different bioactive molecules of tea for their inhibition potency against non structural protein-15 of SARS-CoV-2","volume":"346","author":"Sharma","year":"2021","journal-title":"Food Chem."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"B88","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, Ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1141274","article-title":"The antiviral activity of a small molecule drug targeting the NSP1-ribosome complex against Omicron, especially in elderly patients","volume":"13","author":"Shen","year":"2023","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.1016\/j.bmc.2005.05.065","article-title":"Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic \u03b1,\u03b2-unsaturated esters","volume":"13","author":"Shie","year":"2005","journal-title":"Bioorganic Medicinal Chem."},{"key":"B91","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/v10060283","article-title":"Saracatinib inhibits middle east respiratory syndrome-coronavirus replication in vitro","volume":"10","author":"Shin","year":"2018","journal-title":"Viruses"},{"key":"B92","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.1080\/07391102.2020.1779132","article-title":"Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and nonstructural protein-15: a pharmacoinformatics study","volume":"39","author":"Sinha","year":"2021","journal-title":"J. Biomolecular Structure Dynamics."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/07391102.2020.1762741","article-title":"An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets","author":"Sinha","year":"2020","journal-title":"J. Biomolecular Structure Dynamics"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001967","article-title":"Experimental treatment with favipiravir for ebola virus disease (the JIKI trial): A historically controlled, single-arm proof-of-concept trial in Guinea","volume":"13","author":"Sissoko","year":"2016","journal-title":"PloS Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for covid-19 \u2014 Interim WHO solidarity trial results","volume":"384","author":"Solidarity Trial Consortium","year":"2021","journal-title":"N Engl. J. Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalised with covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl. J. Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.antiviral.2011.12.012","article-title":"A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2","volume":"94","author":"Struck","year":"2012","journal-title":"Antiviral Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/j.cell.2021.02.008","article-title":"In vivo structural characterisation of the SARS-CoV-2 RNA genome identifies host proteins vulnerable to repurposed drugs","volume":"184","author":"Sun","year":"2021","journal-title":"Cell."},{"key":"B99","doi-asserted-by":"publisher","first-page":"137","DOI":"10.14218\/JERP.2021.00032","article-title":"Potential SARS-coV-2 nonstructural protein 15 inhibitors: repurposing FDA-approved drugs","volume":"6","author":"Tang","year":"2021","journal-title":"J. Exploratory Res. Pharmacol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.chembiol.2005.01.006","article-title":"The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus","volume":"12","author":"Tanner","year":"2005","journal-title":"Chem. Biol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with covid-19","volume":"384","year":"2021","journal-title":"N Engl. J. Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1016\/j.drudis.2020.06.017","article-title":"Discovering small-molecule therapeutics against SARS-CoV-2","volume":"25","author":"Tiwari","year":"2020","journal-title":"Drug Discovery Today"},{"key":"B103","doi-asserted-by":"publisher","first-page":"104762","DOI":"10.1016\/j.antiviral.2020.104762","article-title":"Of chloroquine and COVID-19","volume":"177","author":"Touret","year":"2020","journal-title":"Antiviral Res."},{"key":"B104","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s42485-021-00059-w","article-title":"Structure-based inhibitor screening of natural products against NSP15 of SARS-CoV-2 revealed thymopentin and oleuropein as potent inhibitors","volume":"12","author":"Vijayan","year":"2021","journal-title":"J. Proteins Proteom."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.3390\/v15091841","article-title":"Atovaquone and pibrentasvir inhibit the SARS-coV-2 endoribonuclease and restrict infection in vitro but not in vivo","volume":"15","author":"von Beck","year":"2023","journal-title":"Viruses"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1029\/2022GL099529","article-title":"Atmosphere-snow exchange explains surface snow isotope variability","volume":"49","author":"Wahl","year":"2022","journal-title":"Geophysical Res. Lett."},{"key":"B107","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"B108","doi-asserted-by":"publisher","first-page":"8416","DOI":"10.1128\/JVI.00948-15","article-title":"Coronavirus nsp10\/nsp16 Methyltransferase can be targeted by nsp10-Derived peptide in vitro and in vivo to reduce replication and pathogenesis","volume":"89","author":"Wang","year":"2015","journal-title":"J. Virol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature."},{"key":"B110","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl. J. Med."},{"key":"B111","unstructured":"COVID-19 epidemiological update\n          \n          2024"},{"key":"B112","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1128\/AAC.48.7.2693-2696.2004","article-title":"Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide","volume":"48","author":"Wu","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1101\/2020.04.06.026476","article-title":"Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro","volume":"11","author":"Yamamoto","year":"2020","journal-title":"Microbiology"},{"key":"B114","doi-asserted-by":"publisher","first-page":"6532","DOI":"10.1128\/AAC.01043-16","article-title":"Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay","volume":"60","author":"Yamamoto","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2024.02.015","article-title":"Ensitrelvir in patients with SARS-CoV-2: A retrospective chart review","volume":"30","author":"Yamato","year":"2024","journal-title":"J. Infection Chemotherapy"},{"key":"B116","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1016\/j.bmcl.2012.04.081","article-title":"Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13","volume":"22","author":"Yu","year":"2012","journal-title":"Bioorganic Medicinal Chem. Letters."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1097\/CM9.0000000000000790","article-title":"Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir\/ritonavir plus interferon-alpha, and ribavirin plus lopinavir\/ritonavir\u00a0plus\u00a0interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol","volume":"133","author":"Zeng","year":"2020","journal-title":"Chin. Med. J."},{"key":"B118","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature."},{"key":"B119","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses \u2014 drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug Discovery"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1520811\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T06:58:26Z","timestamp":1737615506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1520811\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":119,"alternative-id":["10.3389\/fcimb.2025.1520811"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1520811","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"article-number":"1520811"}}